Enhancement of the transformed shape phenotype by microtubule inhibitors and reversal by an inhibitor combination.

  • Authors:
    • C A Heckman
    • H K Plummer
    • R Mukherjee
  • View Affiliations

  • Published online on: April 1, 2000     https://doi.org/10.3892/ijo.16.4.709
  • Pages: 709-732
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Differences between transformed cells and their normal counterparts were defined by analyzing the cells' three-dimensional distribution of mass. Variables called factors, which explained the covariance of the real variables, were extracted from the data. We found that factors #4 (sharp, tapering projections) and #12 (rounding up), corresponded to G-protein functions. Then, the signature-type mass distribution of transformed cells was defined by factor values. Agents that caused signature-type mimicry could quantitatively shift factor values, for example, those affecting endocytic processing disproportionately reduced values of #4. Signature-type reversal was also observed and may be valuable in predicting the efficacy of chemotherapeutic agents.

Related Articles

Journal Cover

April 2000
Volume 16 Issue 4

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
APA
Heckman, C., Plummer, H., & Mukherjee, R. (2000). Enhancement of the transformed shape phenotype by microtubule inhibitors and reversal by an inhibitor combination.. International Journal of Oncology, 16, 709-732. https://doi.org/10.3892/ijo.16.4.709
MLA
Heckman, C., Plummer, H., Mukherjee, R."Enhancement of the transformed shape phenotype by microtubule inhibitors and reversal by an inhibitor combination.". International Journal of Oncology 16.4 (2000): 709-732.
Chicago
Heckman, C., Plummer, H., Mukherjee, R."Enhancement of the transformed shape phenotype by microtubule inhibitors and reversal by an inhibitor combination.". International Journal of Oncology 16, no. 4 (2000): 709-732. https://doi.org/10.3892/ijo.16.4.709